Piramal Enterprises eyes at acquisition of multiple pharma assets, plans come back into domestic formulations
image for illustrative purpose
Piramal Enterprises Ltd (PEL) is looking at multiple acquisition opportunities across its pharma business, including a possible re-entry into domestic formulations, which the company exited in 2010.
The company, in its FY21 annual report, said that it is looking at acquisitions of niche manufacturing capabilities for a Contract Development and Manufacturing Organisation (CDMO).
A CDMO is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development to manufacturing.
It is also looking at adding new complex hospital generics through in-licensing, acquisitions, and capital investments, and organic and inorganic addition of consumer healthcare products to leverage the pan-India distribution platform and explore re-entry into domestic formulations.
